Diurnal Group PLC Hardman Research: Alkindi®: On route to Europe
December 19 2017 - 7:53AM
RNS Non-Regulatory
TIDMDNL
Diurnal Group PLC
19 December 2017
Hardman Research: Alkindi(R): On route to Europe
Alkindi(R): On route to Europe: Diurnal is a clinical stage
specialty pharmaceutical company focused on diseases of the
endocrine system. Its two lead candidates are targeted at rare
diseases with unmet medical need, with the aim of building a
long-term 'Adrenal Franchise'. Following successful completion of a
Phase III trial, Alkindi(R) (previously known as Infacort(R)) has
received a positive opinion from the CHMP, recommending the
granting of market authorisation for replacement therapy in adrenal
insufficiency for children from birth up to 18 years of age. The
European Commission is expected to grant market approval in
February, allowing first sales in 2Q 2018.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/diurnal-ltd-documents/19-12-17-diurnal.pdf
To contact us: Analysts:
Hardman & Co Dr Martin Hall mh@hardmanandco.com
35 New Broad Street Dr Dorothea Hill dmh@hardmanandco.com
London Dr Gregoire Pave gp@hardmanabdco.com
EC2M 1NH Telephone: +44 20 7194 7622
Follow us on Twitter @HardmanandCo
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFFUFEUFWSELE
(END) Dow Jones Newswires
December 19, 2017 07:53 ET (12:53 GMT)
Diurnal (LSE:DNL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Diurnal (LSE:DNL)
Historical Stock Chart
From Apr 2023 to Apr 2024